FDA approves new interchangeable biosimilar to Perjeta (FDA) - Nov 13, 2025 - "Poherdy is a HER2/neu receptor antagonist indicated for the following: use in combination with trastuzumab and docetaxel for adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease...use in combination with trastuzumab and chemotherapy as: neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence....The recommended initial pertuzumab-dpzb dose is 840 mg administered as a 60-minute intravenous infusion, then followed every three weeks by a dose of 420 mg administered as an intravenous infusion over 30 to 60 minutes."
FDA approval • HER2 Positive Breast Cancer
|